Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)

@article{Andersson2000AllogeneicSC,
  title={Allogeneic stem cell transplantation (BMT) for AML and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy)},
  author={Borje S. Andersson and JosephJ. Gajewski and Mariangela Di Donato and Sergio A. Giralt and Victor Gian and J. Mark Wingard and Stefano Tarantolo and Hugo Schenone Fern{\'a}ndez and Ww Hu and Kellie Blume and Ashwin Kashyap and Stephane Forman and Richard E. Champlin},
  journal={Bone Marrow Transplantation},
  year={2000},
  volume={25},
  pages={S35-S38}
}
Pretransplant conditioning therapy with i.v. BuCy followed by allogeneic hematopoietic stem cell transplantation (BMT) was investigated in a phase II trial in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We gave i.v. Bu at a dose of 0.8 mg/kg every 6 h × 16 doses, followed by Cy 60 mg/kg daily for 2 days. Twenty-six AML patients (18 males/eight females) were treated, only eight of whom were in CR1. The rest were either refractory to induction chemotherapy (four… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 17 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Evaluation of a preparative regimen containing adjusteddose busulfan with stem cell support for the treatment of advanced hematologic malignancies in pediatric patients

  • HT Tran, T Madden, E Felix
  • Blood
  • 1996

Similar Papers

Loading similar papers…